seen from United States
seen from United States
seen from United States
seen from United States
seen from United Kingdom
seen from Uzbekistan
seen from Czechia
seen from Russia
seen from Russia
seen from TĂĽrkiye
seen from United States
seen from United States
seen from Germany
seen from United States
seen from United States
seen from Germany
seen from Italy
seen from Germany
seen from China
seen from United States
ÂżQuĂ© cambia con la nueva pastilla de Merck contra el colesterol LDL? #Colesterol #ColesterolLDL #Lipfendra #Enlicitide #Merck #FDA #SaludCardiovascular #CardiologĂa #Hipercolesterolemia #PCSK9 #Medicamentos #Ciencia #FelizViernes #17DeJulio
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Colesterolo LDL alto? Non aspettare l’infarto per intervenire. La prevenzione sta cambiando — ecco perché
Sapevi che metà degli infarti in Italia colpisce persone senza alcun sintomo pregresso né diagnosi cardiovascolare? Sono circa 300 infarti al giorno “a sorpresa”, su un totale di 600. Persone che si sentivano sane, spesso con il solo — ma pericoloso — “colesterolo alto”. Questo è il messaggio forte lanciato al 86° Congresso della Società Italiana di Cardiologia (SIC): “La sfida del futuro è…
View On WordPress
“Enlicitide”: la pillola orale che può abbattere il colesterolo LDL fino al 60%
Nel panorama della dislipidemia il controllo del colesterolo LDL rappresenta ancora oggi un obiettivo cruciale per la prevenzione delle malattie cardiovascolari. Arriva ora una novità farmacologica che potrebbe rappresentare una svolta: l’agente orale Enlicitide, sviluppato dalla (MSD), che nei trial di fase 3 ha mostrato una riduzione del colesterolo LDL (LDL-C) dell’ordine del 55-60 % rispetto…
View On WordPress
Merck’s oral PCSK9 inhibitor, enlicitide, met all primary & key secondary endpoints in the Phase 3 CORALreef Lipids trial, showing strong LDL-C lowering & a favorable safety profile. A third successful Phase 3 result for the drug. #News #Merck #ClinicalTrials #Cardiology #Hypercholesterolemia
Merck (MSD) has announced positive topline results from the first two Phase III trials of enlicitide decanoate, an investigational oral PCSK9 inhibitor for the treatment of adults with hyperlipidemia. Both trials met their primary and key secondary endpoints. #news #clinicaltrial #hyperlipidemia
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
